The Wall Street Journal: Tissue graft developer MiMedx did not report doctor payments

MiMedx, a fast-growing tissue-graft developer, has financial ties to more than 20 doctors, according to a review of doctors’ disclosures by The Wall Street Journal, but the company hasn’t reported these payments to the government under a 2013 law.

The company says its products, made from donated placental tissue, aren’t among those that require a disclosure of doctor payments. At least one of MiMedx’s MDXG, +3.43% direct competitors, Osiris Therapeutics Inc. OSIR, +6.67% , regularly provides information on its ties to doctors and reported $1.03 million in such payments in 2016.

MiMedx announced Tuesday that its board had engaged independent advisers to review its sales practices.

>>> Original Source <<<